GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Degree of Financial Leverage

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Degree of Financial Leverage : 0.00 (As of Jan. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Cotinga Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Jan. 2020 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Cotinga Pharmaceuticals's Degree of Financial Leverage or its related term are showing as below:

COTQF's Degree of Financial Leverage is not ranked *
in the Biotechnology industry.
Industry Median: 0.96
* Ranked among companies with meaningful Degree of Financial Leverage only.

Cotinga Pharmaceuticals Degree of Financial Leverage Historical Data

The historical data trend for Cotinga Pharmaceuticals's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Degree of Financial Leverage Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cotinga Pharmaceuticals's Degree of Financial Leverage

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cotinga Pharmaceuticals's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Degree of Financial Leverage falls into.



Cotinga Pharmaceuticals Degree of Financial Leverage Calculation

Cotinga Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Jan. 2020 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.075 (Jan. 2020) / -0.132 (Jan. 2019) - 1 )/( -1.814 (Jan. 2020) / -2.63 (Jan. 2019) - 1 )
=-0.4318/-0.3103
=1.39***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Cotinga Pharmaceuticals  (OTCPK:COTQF) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Cotinga Pharmaceuticals Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019